PTC Therapeutics, Inc. (NASDAQ:PTCT) has earned an average recommendation of “Buy” from the ten analysts that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation, four have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $33.83.

A number of research analysts have recently weighed in on PTCT shares. Royal Bank of Canada raised PTC Therapeutics from a “sector perform” rating to an “outperform” rating and set a $11.00 price objective on the stock in a research report on Monday, June 18th. ValuEngine raised PTC Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Monday, June 18th. Credit Suisse Group boosted their price target on PTC Therapeutics from $49.00 to $53.00 and gave the stock an “outperform” rating in a report on Wednesday, September 5th. William Blair raised PTC Therapeutics from a “market perform” rating to an “outperform” rating in a report on Monday, June 18th. Finally, Barclays boosted their price target on PTC Therapeutics from $40.00 to $43.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 8th.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Meeder Asset Management Inc. purchased a new position in PTC Therapeutics in the 2nd quarter worth approximately $137,000. Xact Kapitalforvaltning AB purchased a new position in PTC Therapeutics in the 2nd quarter worth approximately $216,000. Quantitative Systematic Strategies LLC purchased a new position in PTC Therapeutics in the 2nd quarter worth approximately $218,000. CAPROCK Group Inc. purchased a new position in PTC Therapeutics in the 2nd quarter worth approximately $222,000. Finally, Amalgamated Bank purchased a new position in PTC Therapeutics in the 2nd quarter worth approximately $233,000. 85.48% of the stock is currently owned by institutional investors.

Shares of PTCT stock traded down $1.82 during trading hours on Wednesday, reaching $45.37. 848,100 shares of the company traded hands, compared to its average volume of 1,081,228. PTC Therapeutics has a 12-month low of $14.56 and a 12-month high of $52.95. The company has a quick ratio of 4.18, a current ratio of 4.34 and a debt-to-equity ratio of 0.55. The stock has a market cap of $2.40 billion, a P/E ratio of -22.72 and a beta of 1.95.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.15. PTC Therapeutics had a negative return on equity of 27.41% and a negative net margin of 25.03%. The firm had revenue of $68.74 million for the quarter, compared to analysts’ expectations of $69.83 million. equities research analysts expect that PTC Therapeutics will post -1.48 earnings per share for the current fiscal year.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and Emflaza (deflazacort) for treating Duchenne muscular dystrophy.

See Also: How do investors use RSI to grade stocks?

Analyst Recommendations for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.